Analisis Profil Terapi dan Evaluasi Kualitas Peresepan Pada Pasien COVID-19 Rawat Inap di Rs X Jawa Tengah
Therapeutic Profile Analysis and Prescription Quality Assessment for COVID-19 Inpatients Hospital X in East Java
DOI:
https://doi.org/10.30737/jafi.v6i2.6530Keywords:
COVID-19, Prescription Evaluation, Therapeutic ProfileAbstract
COVID-19, caused by SARS-CoV-2, has a high transmission and mortality rate, The variability in therapies administered to patients necessitates an evaluation of treatment patterns among COVID-19 patients to ensure effective therapeutic outcomes. This study aims to analyze the therapy profiles and evaluate prescription patterns of hospitalized patients at General Hospital X, Central Java, based on the COVID-19 Management Protocol, 2nd edition (January 2021). A retrospective descriptive method with purposive sampling was applied to 100 hospitalized COVID-19 patients in 2022. The results showed that the majority of patients were male (55%), aged 40–59 years (45%), had moderate disease severity (77%), a treatment duration of 1–10 days (89%), and a recovery rate of 62%. The most frequently used drug therapies included respiratory medications (19%), gastrointestinal drugs (17%), vitamins (16%), antibiotics (11%), and antivirals (11%). Prescription evaluation revealed 100% drug suitability, 100% correct dosage, 97% appropriate dosing intervals, and 92% correct duration of administration.
References
[1] R. Djalante et al., “Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020,” Progress in Disaster Science, vol. 6, p. 100091, Apr. 2020, doi: 10.1016/j.pdisas.2020.100091.
[2] BPS, “PresentasePenduduk yang Mengobati Sendiri Selama Sebulan Terakhir,” 2021.
[3] C. Zhang, H. Jin, Y. F. Wen, and G. Yin, “Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials,” Front Public Health, vol. 9, Sep. 2021, doi: 10.3389/fpubh.2021.729559.
[4] E. Burhan, A. D. Susanto, S. A. Nasution, E. Ginanjar, C. W. Pitoyo, and A. , et al. , Susilo, “Protokol Tatalaksana COVID-19,” 1st ed., Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI), 2020.
[5] Bhimraj A, Morgan RL, and Hirsch Shumaker A, “Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Infectious Diseases Society of America [Internet],” : https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/.
[6] X. Wu et al., “Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis,” BMC Infect Dis, vol. 24, no. 1, p. 234, Feb. 2024, doi: 10.1186/s12879-023-08754-3.
[7] Kementrian Kesehatan Republik Indonesia, Kementerian Kesehatan RI. Pedoman Pencegahan dan Pengendalian COVID-19. Indonesia, 2021.
[8] Worldometers, “COVID-19 statistics [Internet]. ,” WHO.
[9] R. T. Gandhi, J. B. Lynch, and C. del Rio, “Mild or Moderate Covid-19,” New England Journal of Medicine, vol. 383, no. 18, pp. 1757–1766, Oct. 2020, doi: 10.1056/NEJMcp2009249.
[10] K. Zaher, F. Basingab, J. Alrahimi, K. Basahel, and A. Aldahlawi, “Gender Differences in Response to COVID-19 Infection and Vaccination,” Biomedicines, vol. 11, no. 6, p. 1677, Jun. 2023, doi: 10.3390/biomedicines11061677.
[11] N. U. En Masrika, M. Hasan, Y. Yusran, and S. Buyung, “Karakteristik Pasien COVID-19 di Rumah Sakit Umum Daerah Dr. H. Chasan Boesoirie,” JUMANTIK (Jurnal Ilmiah Penelitian Kesehatan), vol. 7, no. 3, p. 255, Aug. 2022, doi: 10.30829/jumantik.v7i3.11676.
[12] D. R. Karyono and A. L. Wicaksana, “Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia,” Journal of Community Empowerment for Health, vol. 3, no. 2, p. 77, Aug. 2020, doi: 10.22146/jcoemph.57325.
[13] P. Zimmermann and N. Curtis, “Why Does the Severity of COVID-19 Differ With Age?,” Pediatric Infectious Disease Journal, vol. 41, no. 2, pp. e36–e45, Feb. 2022, doi: 10.1097/INF.0000000000003413.
[14] S. Niu et al., “Clinical characteristics of older patients infected with COVID-19: A descriptive study,” Arch Gerontol Geriatr, vol. 89, p. 104058, Jul. 2020, doi: 10.1016/j.archger.2020.104058.
[15] Y. Chen, Q. Liu, and D. Guo, “Emerging coronaviruses: Genome structure, replication, and pathogenesis,” J Med Virol, vol. 92, no. 4, pp. 418–423, Apr. 2020, doi: 10.1002/jmv.25681.
[16] J. Liu et al., “GI symptoms and fever increase the risk of severe illness and death in patients with COVID-19,” Gut, p. gutjnl-2020-321751, Jun. 2020, doi: 10.1136/gutjnl-2020-321751.
[17] S. A. Abrahim et al., “Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia,” PLoS One, vol. 15, no. 12, p. e0244269, Dec. 2020, doi: 10.1371/journal.pone.0244269.
[18] G. Cross, J. S. Y. Ho, W. Zacharias, A. D. Jeyasekharan, and I. Marazzi, “Emergency drug use in a pandemic: Harsh lessons from COVID-19,” Cell, vol. 184, no. 22, pp. 5497–5500, Oct. 2021, doi: 10.1016/j.cell.2021.09.025.
[19] L. Speakman, S. Michienzi, and M. Badowski, “Vitamins, supplements and COVID-19: a review of currently available evidence,” Drugs Context, vol. 10, pp. 1–15, Oct. 2021, doi: 10.7573/dic.2021-6-2.
[20] A. U. P. Ningrum, R. Andrajati, N. F. Syafhan, and A. Wirawan, “Effectiveness of COVID-19 Antivirus Therapy and Its Relationship with Vaccination: A Retrospective Analysis,” Jurnal Respirologi Indonesia, vol. 43, no. 3, pp. 195–203, Jul. 2023, doi: 10.36497/jri.v43i3.434.
[21] C. Kim et al., “Antibiotic Use Among Hospitalized Patients With COVID-19 in the United States, March 2020–June 2022,” Open Forum Infect Dis, vol. 10, no. 11, Nov. 2023, doi: 10.1093/ofid/ofad503.
[22] Y. Furuta, T. Komeno, and T. NAKAMURA, “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase,” Proceedings of the Japan Academy, Series B, vol. 93, no. 7, pp. 449–463, 2017, doi: 10.2183/pjab.93.027.
[23] Y. Wang et al., “Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection,” J Infect Dis, vol. 221, no. 10, pp. 1688–1698, Apr. 2020, doi: 10.1093/infdis/jiz656.
[24] G. P. Mishra and J. Mulani, “Corticosteroids for COVID-19: the search for an optimum duration of therapy,” Lancet Respir Med, vol. 9, no. 1, p. e8, Jan. 2021, doi: 10.1016/S2213-2600(20)30530-0.
[25] E. J. Cano et al., “Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes,” Chest, vol. 159, no. 3, pp. 1019–1040, Mar. 2021, doi: 10.1016/j.chest.2020.10.054.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Okky Intan Mawarni, Winartiana winartiana, Elsa Mahardika Putri, Maharani Dwi Pratiwi, Pulung Prabowo, Elly Rakhmawati Ratnanigrum
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Penulis menyimpan hak cipta dan memberikan jurnal hak penerbitan pertama naskah secara simultan dengan lisensi di bawah Creative Commons Attribution License yang mengizinkan orang lain untuk berbagi pekerjaan dengan sebuah pernyataan kepenulisan pekerjaan dan penerbitan awal di jurnal ini.
- Penulis bisa memasukkan ke dalam penyusunan kontraktual tambahan terpisah untuk distribusi non ekslusif versi kaya terbitan jurnal (contoh: mempostingnya ke repositori institusional atau menerbitkannya dalam sebuah buku), dengan pengakuan penerbitan awalnya di jurnal ini.
- Penulis diizinkan dan didorong untuk mem-posting karya mereka online (contoh: di repositori institusional atau di website mereka) sebelum dan selama proses penyerahan, karena dapat mengarahkan ke pertukaran produktif, seperti halnya sitiran yang lebih awal dan lebih hebat dari karya yang diterbitkan.
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/ojs.unik-kediri.ac.id/public_html/plugins/generic/citations/CitationsPlugin.php on line 68
